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Strong competition between cytotoxic T-lymphocytes (CTLs) speciﬁc for different epitopes in human
immunodeﬁciency virus (HIV) infection would have important implications for the design of an HIV
vaccine. To investigate evidence for this type of competition, we analysed CTL response data from
97 patients with chronic HIV infection who were frequently sampled for up to 96 weeks. For each
sample, CTL responses directed against a range of known epitopes in gag, pol and nef were measured
using an enzyme-linked immunospot assay. The Lotka–Volterra model of competition was used to pre-
dict patterns that would be expected from these data if competitive interactions materially affect CTL
numbers. In this application, the model predicts that when hosts make responses to a larger number of
epitopes, they would have diminished responses to each epitope and that if one epitope-speciﬁc response
becomes dramatically smaller, others would increase in size to compensate; conversely if one response
grows, others would shrink. Analysis of the experimental data reveals results that are wholly inconsistent
with these predictions. In hosts who respond to more epitopes, the average epitope-speciﬁc response
tends to be larger, not smaller. Furthermore, responses to different epitopes almost always increase in
unison or decrease in unison. Our ﬁndings are therefore inconsistent with the hypothesis that there is
competition between CTL responses directed against different epitopes in HIV infection. This suggests
that vaccines that elicit broad responses would be favourable because they would direct a larger total
response against the virus, in addition to being more robust to the effects of CTL escape.
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1. INTRODUCTION
In human immunodeﬁciency virus-1 (HIV-1) infection,
the cytotoxic T-lymphocyte (CTL) response is typically
focused towards a handful of epitopes (Scherer et al.
2004). There is variation in the magnitude of the response
to each epitope, and it has been argued that this apparent
hierarchy is the result of competition between CTLs of
different epitope speciﬁcities (Nowak et al. 1995).
Whether there is competition between CTL populations
directed against different epitopes has important impli-
cations for HIV vaccine design. Arguably, a vaccine that
induces a broad CTL response would be favourable by
directing a large total response against the virus and
by being more robust if escape occurs. If, however,
competition largely shapes the anti-HIV CTL repertoire,
then a broader response may not be desirable because
ineffective responses could suppress effective responses.
As yet, research into competition in HIV-1 infection is
limited, though competition between CTLs has been
shown to occur in mice in response to infection with
herpes simplex virus-1 (Stock et al. 2006), inﬂuenza
virus (Chen et al. 2000; Andreansky et al. 2005) and lym-
phocytic chroriomeningitis virus (Butz & Bevan 1998).
Kedl et al. (2003) presented a review of the extensive
body of research into T-cell competition in mice. They
highlighted that competition can occur between CTLs
speciﬁc for the same epitope (epitope-speciﬁc or inter-
speciﬁc competition) (Butz & Bevan 1998; Sandberg
et al. 1998; Wolpert et al. 1998; Grufman et al. 1999a,b;
Kedl et al. 2000, 2002; Smith et al. 2000; Probst
et al. 2002) and between CTLs speciﬁc for different
epitopes (intraspeciﬁc competition) (Sandberg et al.
1998; Wolpert et al. 1998; Grufman et al. 1999b; Chen
et al. 2000; Kedl et al. 2000), though evidence for intras-
peciﬁc competition is less compelling. In one experiment
involving adoptive transfer of T-cells, it was shown that
intraspeciﬁc competition is far less efﬁcient than inter-
speciﬁc competition (Kedl et al. 2002) and in another
there was no evidence of intraspeciﬁc competition at all
(Probst et al. 2002). Similarly, deletion of dominant
viral or bacterial epitopes has failed to signiﬁcantly
enhance responses directed against previously sub-
dominant epitopes (Moskophidis & Zinkernagel 1995;
Weidt et al. 1998), and in one such experiment, responses
were not enhanced at all (Vijh et al. 1999).
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antigen-presenting cells (APCs) have been shown to
play a crucial role (Kedl et al. 2003). These cells present
epitopes to naive T-cells, resulting in activation and
proliferation of the T-cells speciﬁc to the epitopes pre-
sented. In epitope-speciﬁc competition, CTLs appear to
downmodulate the level of the epitope presented on the
APC after interaction with the APC (Kedl et al. 2002).
This loss of antigens inhibits activation of other T-cells
with the same speciﬁcity, particularly those with lower
afﬁnity for the epitope. Competition may also occur for
access to antigens and costimulatory molecules at the
APC surface. In intraspeciﬁc competition, down-
modulation does not feature; instead it is thought
that competition results solely from limited access to the
surface of APCs (Wolpert et al. 1998; Borghans et al.
1999; Grufman et al. 1999b). The role of APCs in
intraspeciﬁc competition is conﬁrmed by the observation
that intraspeciﬁc competition is abolished when different
epitopes are presented on different APCs (Kedl et al.
2000).
With regard to competition between CTLs in HIV-1,
one report by Nowak et al.( Nowak et al. 1995) presented
data from two humans that demonstrate ﬂuctuations in
the CTL response directed against different epitopes
and against different variants—i.e. mutant and wild-
type—of the same epitope. In some cases, a decrease in
one response coincided with an increase in another
response, but whether these dynamics were driven by
competition, rather than simply changes in the circulating
virus strains, was unclear (Nowak et al. 1995). In a more
comprehensive study (Altfeld et al. 2006), it was shown
that the response to epitopes restricted by HLAs A1, A2
and A3 was lower in humans who also expressed HLA
B57 or HLA B27 compared with those who did not
express HLA B57 or HLA B27. The inference was that
strong responses to the immunodominant epitopes
TSTLQEQIGW (B57-restricted) and KRWIILGLNK
(B27-restricted) compete with and suppress responses
to other epitopes. Evidence for intraspeciﬁc competition
also comes from mice immunized with CTL epitopes
from different clades of HIV-1 (Larke et al. 2007).
During single-clade immunization, a potent response
was observed to the clade B epitope AMQMLKETI,
but this was ablated when the mice were simultaneously
immunized with the clade A version of this epitope,
AMQMLKDTI.
Detecting competition in whole organism ecology is a
well-known, thorny problem. It can be very difﬁcult to
manipulate the abundance of individual species or
groups of species in a natural setting (Dybzinski &
Tilman 2009). Even if such manipulations are successful,
it can be hard to interpret experimental outcomes. For
example, if removing one species leads to no change in
the density of its putative competitors is that because
they are (and always have been) genuinely independent
of each other, or is it that the species assemblage has
grown up to minimize competitive interactions (Connell
1980)? Even if experimental removal of one species
demonstrably leads to increases in the abundance of its
competitors, questions remain about the mechanisms of
competition. Were they competing for shared resources
(Tilman 1982) or did they instead share predators at a
higher trophic level (Holt 1977)? Careful combinations
of mathematical models, observational data and exper-
imental manipulations have led, over the past several
decades, to much richer interpretations of the processes
that drive the assembly of species into communities
(reviewed in Keddy 2001; Tilman 2007). Although that
theory was developed to explain whole organism ecology,
much of it could be borrowed or adapted to explore the
diversity of immune responses within individuals
(McLean et al. 1997).
In this study, we investigate evidence for competition
between CTL responses speciﬁc for different epitopes in
HIV-1 infection by analysing CTL responses made by
97 chronically infected HIV-1 patients who were enrolled
onto an intermittent therapy trial. Patients were fre-
quently sampled for up to 96 weeks. For each sample,
CTL responses directed against a range of known
epitopes were measured using an enzyme-linked immu-
nospot (ELISPOT) assay. To test for competition, we
compared these data with the results predicted by the
Lotka–Volterra model of competition. Speciﬁcally, we
asked the following two questions:
(i) If many responses are present, is each response
smaller?
(ii) If one epitope-speciﬁc response becomes dramatically
smaller, do others increase in size in apparent
compensation, and conversely if one response
grows, do others shrink?
2. MATERIAL AND METHODS
(a) Patient cohort and study design
Ninety seven patients from Switzerland were recruited onto
the Swiss–Spanish Intermittent Therapy Trial (SSITT), a
large study devised to assess the clinical, virological and
immunological outcome of structured treatment interrup-
tions in individuals with chronic HIV infection. These
individuals all gave informed consent before participating
in the study and have been described and studied in detail
elsewhere (Oxenius et al. 2002b; Scherer et al. 2004; Frater
et al. 2007). Patients were only included in the study if
their CD4 count was above 300 cells per mm
3 at the time
of enrolment and if they had been on continuous antiretro-
viral therapy (ART) with a plasma viral load less than
50 copies per ml for at least six months. The treatment
interruption schedule required that ART was stopped at
week 0 for two weeks, and resumed thereafter for eight
weeks (weeks 2–10). This cycle was then repeated four
times. Patients resumed continuous therapy and were
removed from the study if their viral load persisted above
50 copies per ml during any of the periods on therapy.
Patients were also removed from the study at week 40 if
their CD4 count was less than 400 cells per mm
3. For all
other patients, therapy was stopped at week 40 for up to
56 weeks, i.e. until week 96, and was only resumed if symp-
toms associated with acute infection arose, or if viral load
exceeded 500000 copies per ml once, 100 000 copies
per ml twice or 50 000 ml three times. While patients
remained on the study, they provided blood samples at fre-
quent intervals. The mean number of times that patients
were sampled was 11 (range 1–24) and the mean period
across which these samples were taken was 58 weeks (range
0–96 weeks).
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and HLA typing
Plasma viral load was quantiﬁed throughout the study from
cryopreserved plasma by using the regular or the ultrasensi-
tive (for measurements taken on ART) Roche HIV
Monitor assay (Roche Diagnostics, Rotkreuz, Switzerland;
limit of detection 200 and 50 copies per ml). Viral loads ﬂuc-
tuated with the treatment cycles (Oxenius et al. 2002b), but
remained comparatively stable beyond week 50, 10 weeks
after the ﬁnal cessation of therapy. As part of a study into
immune escape mutants (Frater et al. 2007), viral DNA
was extracted from peripheral blood mononuclear cells
(PBMCs) collected while the patients were off therapy.
HIV-1 gag, pol and nef genes were ampliﬁed by nested PCR
and sequenced using ABI Big Dye terminator sequencing
kits. Sequences were available from 88 of the Swiss patients,
and the Rega Subtyping Tool (http://dbpartners.stanford.
edu/RegaSubtyping/) was used to subtype these individuals.
Seventy six per cent of the patients were found to be
clade B. For each individual, human leukocyte antigen
(HLA) class I genotypes were also determined by PCR
using sequence-speciﬁc primers.
(c) IFN-g enzyme-linked immunospot assay
Throughout the study, CTL responses directed against
peptides representing clade B optimal epitopes were
measured ex vivo by gamma interferon production using an
interferon-gamma (IFN-g) ELISPOT assay (Oxenius et al.
2002b; Scherer et al. 2004). All but three of the epitopes
tested had sequences equal to the HXB2 reference strain
and responses were measured in terms of the number of
spot-forming cells (SFC) per million PBMCs above the
background level. According to HLA type, patients were
screened against a median of 17 (range 0–31) peptides;
across all HLA types, 80 peptides were tested. A description
of the epitopes and the full set of data used in our analysis are
presented in spreadsheet S1 in the electronic supplementary
material. In addition, an example of the CTL response data
available for a single individual is presented in table S1 in the
electronic supplementary material.
(d) Analysis of cytotoxic T-lymphocyte
response data
To understand how the mean CTL response per epitope
correlates with the number of epitopes targeted, the CTL
response data was ﬁrst analysed from a cross-sectional per-
spective. For each patient, at each time point, the number
of screened epitopes that the patient made a response to
was compared with the mean response per epitope. Only
responses greater than 50 spot-forming cells (SFCs)/10
6
PBMCs were regarded as positive responses in this analysis.
For example, patient 72 was tested at 12 different time
points, recording between 0 and 4 CTL responses at each
time point. For each time point tested, this patient contributed
a single data point relating the number of responses to the
mean response size. Raw data for this patient (and all
others) are given in electronic supplementary material,
spreadsheet S1, and details of this cross-sectional data treat-
ment are given in table S1b in the electronic supplementary
material. MINITAB statistical package was used to ﬁt a linear
correlation between these two variables by weighted least-
squares regression analysis. Using MINITAB, we also
calculated the Pearson correlation coefﬁcient (PCC) and
the p-value relating to a two-sided hypothesis test in which
the null hypothesis is that the PCC is zero.
To understand how large changes in the response to
speciﬁc epitopes correlate with changes in the total response
directed against all other epitopes, the SSITT data were also
analysed longitudinally. Since changes in the CTL response
could occur in response to changes in viral load caused by
therapy interruption, only data from week 50 and beyond
were analysed for this part of the study. By this stage patients
would have been off therapy for 10 weeks, therefore ﬂuctu-
ations in CTL responses caused by therapy interruptions
should no longer occur. Indeed, beyond this point, there
was no evidence of systematic increases in either the viral
load, the breadth of CTL responses or the magnitude of
CTL responses over time. For each epitope, the difference
in the response between available sample times for each com-
bination of two sample times was calculated and the largest
difference (in magnitude) observed in a single epitope was
determined. The corresponding total change in the responses
directed against all other screened epitopes at that time was
also determined and the relationship between these two vari-
ables was calculated and tested using MINITAB, as described
above. For example, patient 72 was screened at four time
points after week 50, yielding six possible longitudinal com-
parisons. The largest difference in response to a single
epitope was seen in the response to DTGHSNQVSQNY
that rose from 26 SFCs/10
6 PBMCs at week 56 to 2843 at
week 72 (an increase of 2817 SFCs/10
6 PBMC). Over the
same period, the sum of the responses to all other epitopes
rose from 815 to 4292 SFCs/10
6 PBMC (an increase of
3477 SFCs/10
6 PBMCs), hence it is these two vectors
(þ2817 and þ3477) that represent the longitudinal data
from this patient (raw data in spreadsheet S1 and this analy-
sis in the electronic supplementary material, table S1c). For
completeness, we performed the same analysis on data
from the whole time period that patients were studied.
(e) Lotka–Volterra model of competition
To understand what patterns we would expect to see in the
SSITT ELISPOT data under competition, we have investi-
gated the dynamics of the Lotka–Voltera competition model
(Volterra 1926; Lotka 1932; Murray 1989). For certain par-
ameter sets, this model represents a system where n distinct
populations can coexist in the setting of competition between
both elements of the same population and elements of differ-
ent populations. Here, we have used this model to represent
competition between different populations of CTLs speciﬁc
for different epitopes. The model can be expressed as a set
of ordinary differential equations (equation (2.1)).
dNi
dt
¼ riNi 1  
Ni
Ki
 
1
Ki
X
j¼1:n
j=i
aijNj
0
B B @
1
C C A i ¼ 1 : n: ð2:1Þ
Ni refers to all the CTLs speciﬁc to one epitope (epitope i),
which, from here on we will call a speciﬁcity. Population
growth is density dependent, and in the absence of compe-
tition, the per capita growth rate of each CTL population is
ri. For each speciﬁcity, growth is regulated by the carrying
capacity, Ki. This means that when all CTL populations
speciﬁc to other epitopes are absent, the population size of
speciﬁcity i would increase if its size (Ni) were below the car-
rying capacity and decrease if its size were above the carrying
capacity. In real terms, the carrying capacity for CTLs
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the presence of the components necessary for inducing an
immune response to that particular epitope. This may include
the abundance of the epitope presented on the surface of
infected cells and/or APCs and the afﬁnity that CTLs have
for the epitope. In the model, competition between CTLs
of different speciﬁcities can occur for those components
required by all CTLs, such as the basic level of antigens
presented. The competition coefﬁcient, aij, represents the
effect that the CTL population of speciﬁcity j has on that of
speciﬁcity i.I faij ¼ 1, then the survival of CTLs of speciﬁcity
i is affected equally by the presence of CTLs of speciﬁcity j
as by the presence of other CTLs of speciﬁcity i, whereas if
aij ¼ 0, then the two speciﬁcities act independently. Different
populations can coexist provided the effect of interspeciﬁc
competition on each population is less important than the
effect of intraspeciﬁc competition. In the simplest case of
this model, where there are CTLs speciﬁc for two epitopes
(n ¼ 2), coexistence is possible provided K1 . a12K2 and
K2 . a21K1, that is, provided a12 and a21 are sufﬁciently
small in comparison with the carrying capacities, K1 K2.
For our analysis, we use this model to represent the scen-
ario where coexistence of CTL populations speciﬁc to several
epitopes is possible, since in HIV infection CTL responses
are typically maintained against several epitopes within
each host (Scherer et al. 2004). Figure 1a demonstrates the
basic dynamics of three CTL populations of different speci-
ﬁcities, as prescribed by this model. If the number of CTLs
speciﬁc for each epitope is initially low, each population
increases before settling at an equilibrium, which is deter-
mined by the degree of competition between the different
CTL populations and the carrying capacities of the different
speciﬁcities (ﬁgure 1a(i)(ii)). These equilibria are locally
stable for most parameter values; therefore, if a sporadic
decrease (or increase) occurs in the number of CTLs speciﬁc
for one epitope, after a period of time the equilibria will
be regained. In the interim, there will be a temporary
increase (or decrease) in CTLs directed against other epi-
topes if competition occurs (ﬁgure 1a(iii)), but no change
if no competition occurs (ﬁgure 1a(iv)). A second way in
which the response directed against one epitope could
change is if the carrying capacity of the epitope decreases
(or increases). Rather than representing a sporadic change,
this would represent a change in the ability of that particular
CTL population to thrive irrespective of competition.
An example might be a reduction in antigens bearing the
wild-type epitope after outgrowth of an escape mutant.
As above, if there is competition, then the long-term decline
of CTLs of one speciﬁcity would coincide with the long-
term growth of CTLs of other speciﬁcities. However, in
this case the distinct CTL populations would settle at differ-
ent (stable) equilibria (ﬁgure 1a(v)). If there is no
competition, other CTL populations will not be affected
(ﬁgure 1a(vi)).
3. RESULTS
(a) If many responses are present, is each
response smaller?
To investigate whether there is competition between CTL
responses directed against different epitopes, we ﬁrst
compared actual measurements with model predictions
as to how the mean response per epitope correlates with
the number of epitopes targeted.
Using the Lotka–Volterra model, we compared scen-
arios in which different numbers of CTL populations,
each with the same carrying capacity, coexist. To compare
these scenarios under competition we assumed that the
degree of interspeciﬁc competition is the same regardless
of the number of epitopes targeted and the same for each
competitive interaction (aij ¼ a for all i and j, except i ¼ j).
Figure 1b shows that the mean response per epitope
would decrease as the number of epitopes targeted
increases (dashed line). If, however, there is no
interspeciﬁc competition (aij ¼ 0 for all i and j, except
i ¼ j), then the mean response per epitope would
be independent of the number of epitopes targeted
(solid line).
We analysed the SSITT data to see how the mean
response per epitope correlates with the number of
screened epitopes targeted. This analysis was separately
performed on data collected at each sample time and it
was found that at the majority (90%) of sample times
the mean response per epitope increased with the
number of epitopes targeted (ﬁgure 2a of the main text
and ﬁgure S1 in the electronic supplementary material),
the opposite of what is predicted by the Lotka–Volterra
model. At the remaining sample times, the mean response
decreased as the number of epitopes targeted increased,
though in no case was the negative correlation statistically
signiﬁcant. Taken together, these data therefore provide
no evidence that competition exists between CTLs
speciﬁc for different epitopes. Rather, they suggest that
some overriding external factor drives the magnitude
and breadth of the CTL response to increase or decrease
in unison, or that CTLs are cooperative.
(b) If one epitope-speciﬁc response becomes
dramatically smaller, do others increase in
size to compensate, and conversely if one response
grows, do others shrink?
Next we investigated whether the within-host dynamics of
CTL responses suggest that there is competition between
responses. We compared data and model predictions of
how large changes in one epitope-speciﬁc response corre-
late with changes in the responses directed against other
epitopes. We used the Lotka–Volterra model to represent
the dynamics of different coexisting CTL populations
following a change in the carrying capacity of one
epitope-speciﬁc CTL population. A change in carrying
capacity drives a change (in the same direction) in the
number of CTLs speciﬁc for that epitope. If there is com-
petition between this epitope-speciﬁc CTL population
and others, then an increase in the response to this
epitope would result in a decrease in the total response
directed against all other epitopes. Similarly, a decrease
in the response to this epitope would result in an increase
in the total response directed against other epitopes
(ﬁgure 1c; dashed line, negative correlation). If, by con-
trast, there is no interspeciﬁc competition, then a
change in the response to one epitope would not affect
the response to any other epitopes (ﬁgure 1c; solid line,
no correlation).
We analysed the CTL response data from week 50 and
beyond to ﬁnd how largechanges in the response toparticu-
larepitopescorrespondtochangesintheresponsetoallother
epitopes. To perform this analysis, for each patient we
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Figure 1. (Caption overleaf.)
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any epitope between any two time points and the change in
the total response to all other epitopes over the same
period. Figure 2b shows that there is a very strong positive
correlation between these two variables (PCC ¼ 0.897;
p , 0.001), the opposite of what would be expected in a set-
ting of interspeciﬁc competition. These ﬁndings were
repeated when data from all time points were analysed
(PCC ¼ 0.690; p , 0.001; datanot shown). The dynamical
interpretation of the SSITT data is therefore also inconsist-
ent with the existence of interspeciﬁc competition and
instead reveals that expansions or contractions in different
CTL populations occur in unison, either in response to
other inﬂuential factors or through cooperation.
In summary, two patterns found in the CTL response
data are inconsistent with predictions made by the
Lotka–Volterra model under the assumption of compe-
tition between CTLs speciﬁc for different epitopes.
Firstly, the mean response per epitope increases as the
breadth of the response increases and, secondly, CTL
responses against different epitopes tend to increase in
unison or decrease in unison. Our very simple models
of competition make no assumptions about what CTLs
might be competing for. A different approach is to expli-
citly deﬁne that CTLs are competing for viral antigens. It
is natural to ask whether models that include competition
for antigens and acknowledge the antigenic diversity of
HIV and corresponding effects on viral dynamics could
explain the patterns we see. Certainly, it seems plausible
that two or more competing CTLs could simultaneously
ﬂuctuate if antigens speciﬁc for those particular CTLs
simultaneously ﬂuctuate in the same direction. This
could occur if the total level of all antigens ﬂuctuates or
if there are more isolated simultaneous ﬂuctuations in
the speciﬁc antigens considered. A model by Nowak
et al. (1995) includes antigenic diversity and competition
by CTLs for antigens and shows that the combination of
these two factors could lead to complicated oscillatory
dynamics of different viral strains and different CTL
speciﬁcities. Among these dynamics, there are large ﬂuc-
tuations in the total abundance of virus, with the peaks
being largely dominated by speciﬁc viral variants.
Furthermore, competing CTLs targeting epitope variants
that are linked on particular viral strains can simul-
taneously ﬂuctuate in coincidence with ﬂuctuations
in those viral strains. By association, simultaneous
ﬂuctuations in CTLs also tend to coincide with changes
in the total viral abundance. Finally, according to the
Nowak model, patterns of simultaneous ﬂuctuations of
CTLs targeting linked epitope variants would become
less marked with increased cross reactivity and with an
increase in ‘mixed’ strains caused by recombination. So
how do these issues affect how we should interpret the
patterns that we have observed in our patients? To under-
stand whether the total viral abundance is linked to the
patterns we see, we have investigated how CTL responses
compare to plasma viral load. We have found that changes
in total viral abundance do not explain the patterns
that we have observed. The breadth of the CTL
response does not correlate with the log viral load
(electronic supplementary material, ﬁgure S2a; e.g.
PCC ¼ 20.144, p ¼ 0.261 at week 0 and PCC ¼ 0.074,
p ¼ 0.699 at week 64) and large changes in epitope-
speciﬁc responses do not correlate with changes in log
viral load (electronic supplementary material, ﬁgure S2b;
PCC ¼ 0.065, p ¼ 0.731). This still leaves the question
of whether changes in the abundance of speciﬁc viral
variants (but not the total viral abundance) could cause
the patterns we see. We are not able to address this ques-
tion directly because the extensive sequence data that
would be required were not collected from our patients.
From an indirect perspective, however, changes in
the abundance of speciﬁc viral variants is not a valid expla-
nation because we tend to see simultaneous ﬂuctuations in
the response to most, if not all, targeted epitopes within
each individual (data not shown). Taken together, infer-
ences from simple and complex models therefore suggest
that our data provide no evidence in favour of competition
between CTLs speciﬁc for different epitopes.
Our ﬁndings are contradictory to data presented
by Altfeld et al. (2006), showing that hosts who
express HLA B27 or HLA B57—alleles that induce
Figure 1. (Overleaf.) Model predictions. (a) Predicted behaviour under the Lotka–Volterra model in the presence and absence of
competition between HIV-specifc CTL speciﬁcities. In (i), (iii) and (v), there is competition between CTLs speciﬁc for different
epitopes, whereas in (ii), (iv) and (vi), there is no competition (aij ¼ 0f o ra l li and all j, i = j). In (i) and (ii) there is no change in
CTL speciﬁc for either of three epitopes. In (iii) and (iv) there is a sporadic decrease in CTL speciﬁc for one of three epitopes
(epitope 3). In (v) and (vi) there is a decrease in the carrying capacity of CTL speciﬁc for epitope 3. The ﬁgures show that if a
decrease (or increase) occurs in the response to one epitope, then other responses will increase (or decrease) if there is competition
between speciﬁcities. Changes in other responses will be temporary following a sporadic change in the response to one epitope,
but permanent following a change in the carrying capacity of one epitope. The following model parameters were used: K1 ¼ 900,
K2 ¼ 800 and K3 ¼ 700; ri ¼ 30 for all i and aij ¼ 0.4 for all i and all j when there is competition. The starting values were Ni(0) ¼
0f o ra l li. In (iii) and (iv), the response to epitope 3 decreases by 200 at time t ¼ 1.5 years. In (v) and (vi), the carrying capacity for
CTLs directed against epitope 3 decreases to 600 at t ¼ 1.5 years. Dashed lines, epitope 1; solid lines, epitope 2; dashed-dotted
lines, epitope 3. (b) Model prediction of how the mean response per epitope varies with the number of epitopes targeted. If there is
no interspeciﬁc competition (solid line), the mean response does not vary with the number of epitopes targeted, whereas if there is
interspeciﬁc competition (dashed line) (aij . 0f o rs o m ei and j), the mean response per epitope decreases with the number of
epitopes targeted. For this example, we have assumed that the carrying capacity, Ki, of each epitope-speciﬁc response is the
same (Ki ¼ 1000) and that interspeciﬁc competition between each speciﬁcity is as strong as intraspeciﬁc competition (aij ¼ 1
for all i and j). In this particular case, the mean response is inversely proportional to the number of epitopes targeted.
(c) Model prediction of how the change in the response directed against a single epitope would correspond to the change in
the sum of the responses directed against other epitopes. If there is no interspeciﬁc competition, signiﬁcant changes in the
response directed against one epitope would not correspond to changes in the total response directed against other epitopes
(solid line). If there is interspeciﬁc competition, an increase in the response directed against one epitope would correspond to
a decrease in the total response directed against other epitopes (dashed line). These changes would be exactly equal in magnitude
(as shown) if interspeciﬁc competition is as strong as intraspeciﬁc competition.
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responses to other epitopes. We repeated their analysis on
our data, but we were unable to reproduce their results. In
the presence of HLA B27/B57, responses to epitopes
restricted by HLAs A1, A2 and A3 were no lower
than in the absence of HLA B27/B57 (electronic
supplementary material, ﬁgure S3).
4. DISCUSSION
In this study, we have investigated evidence for compe-
tition between CTLs speciﬁc for different epitopes in
HIV-1 infection. Analysis of CTL response data from a
large cohort of chronically infected patients has revealed
that this type of competition does not materially affect
CTL numbers. We compared CTL response data with
model predictions of how the mean response per epitope
should correlate with the breadth of the response and how
large changes in the response to one epitope should cor-
relate with changes in the response to other epitopes.
We found that the mean response per epitope increases
as the breadth of the response increases and that large
expansions in the response to one epitope correlate with
expansions in the response to other epitopes. Both of
these results are in contrast to the predictions made
using the Lotka–Volterra model under the assumption
of competition between CTLs speciﬁc for different
epitopes. Our data are therefore inconsistent with the
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Figure 2. Observations from the SSITT data. (a) Patients with more responses make larger responses. A scatter plot and ﬁtted
line showing that there is a positive correlation between the mean response per epitope and the number of epitopes targeted for
samples taken at (i) week 0 (not signiﬁcant; PCC ¼ 0.167, p ¼ 0.191) and (ii) week 19 (signiﬁcant; PCC ¼ 0.405, p ¼ 0.001),
the two weeks with the most number of patients sampled (week 0, n ¼ 73 and week 19, n ¼ 69). When the same analysis was
performed on the response data from each of the 29 different sampling times, a positive correlation was found at 26 sample
times. Twelve of the positive correlations and none of the negative correlations were signiﬁcant. The full analysis is presented
in ﬁgure S1 in the electronic supplementary material. (b) A large change in one epitope-speciﬁc response is accompanied by
changes in the same direction in other responses. A scatter plot and ﬁtted line showing how the largest change in response
directed against a single epitope corresponds to changes in the response directed against other epitopes. There is a striking posi-
tive correlation between these two variables (PCC ¼ 0.897, p , 0.001), i.e. responses to different epitopes increase in unison or
decrease in unison. Only changes corresponding to week 50 and beyond were included in this analysis. The data from each
patient are represented by a single cross. The same pattern is observed when data from all sample times are analysed
(PCC ¼ 0.690, p , 0.001; data not shown).
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Instead they imply that CTL populations directed against
different epitopes are cooperative or that external
variables are the overriding inﬂuence on CTL numbers
and affect different CTL populations in the same way.
Antigenic stimulus is an obvious candidate for such an
external variable; however, detailed analysis of the viral
load data does not support this suggestion, adding
weight to the assertion that CTLs speciﬁc for different
epitopes do not compete.
Although these data show no signature that
competition is acting between subspeciﬁcities of the
HIV-speciﬁc response, there is clear evidence that at
the level of the whole population—whether B cells
(McLean et al. 1997) or T-cells (Veiga-Fernandes et al.
2000)—lymphocytes are subject to competitive inter-
actions. Previous studies into competition between
CTLs speciﬁc for different epitopes in mice have also
revealed mixed ﬁndings. Some are in agreement with
ours and have shown intraspeciﬁc competition to be
absent or insigniﬁcant (Moskophidis & Zinkernagel
1995; Weidt et al. 1998; Kedl et al. 2002; Probst et al.
2002), whereas others have revealed evidence in favour
of intraspeciﬁc competition (Sandberg et al. 1998;
Wolpert et al. 1998; Grufman et al. 1999b; Chen et al.
2000; Kedl et al. 2000). Recent modelling work (Scherer
et al. 2006) suggests that these differences could stem
from the level at which epitopes are expressed on APCs
in these different studies. Scherer and colleagues found
that at low per APC expression levels CTLs compete
for access to their cognate epitope, so there is competition
between CTLs speciﬁc for the same epitope but
not between CTLs speciﬁc for different epitopes. At
high epitope expression levels, however, competition
becomes aspeciﬁc, namely for access to the surface of
the APC, resulting in intraspeciﬁc competition.
Our ﬁndings have important implications for HIV
vaccine design since in the absence of competition any
manipulation that broadens the CTL response could be
beneﬁcial by providing a larger total response against
the virus and by providing a response that is more
robust in the event of CTL escape in one or more epi-
topes. Further studies into competition between CTLs
in HIV in different scenarios are crucial. The study we
have presented was performed on patients who had estab-
lished infections and competition may, for example, be
present or more important during the initial response to
the virus during acute infection or just after vaccination.
Other factors that need to be ruled out as being inﬂuential
to our ﬁndings are the method for the measurement of
CTL responses and the patient cohort. Firstly, we note
that for future studies, measurement of absolute numbers
of CTL in a given volume of blood may be more informa-
tive than the ‘prevalence’ measure used here of the
number of SFCs in a given number of PBMCs. Crucially
though, a prevalence measure is intrinsically biased
towards detecting a signature of competition even when
none exists, meaning that our inference of no competition
holds despite the counting method. Secondly, we note
that the ELISPOT technique used here to measure
interferon-g has failed to explain differences between
the magnitude of CTL responses and their effect on
viral clearance rates (Oxenius et al. 2002a) and therefore
may not reﬂect the true efﬁcacy of the response. More
recent studies indicate that the number of polyfunctional
CTLs correlate with plasma viral load (Betts et al. 2006;
Daucher et al. 2008), and it would therefore be interesting
to investigate whether lack of competition is also observed
when polyfunctional CTLs are measured. Thirdly, we
acknowledge that many CTL epitopes to which patients
make responses (wild-type and mutant variants) have
not been screened in this study. Nevertheless, our
ELISPOT dataset is one of the largest and most compre-
hensive to date and the patterns that we have observed are
very clear. It is therefore likely that more comprehensive
studies would reveal the same patterns. Finally, we note
that different patient cohorts should also be investigated.
The SSITT patients used in this study were unusual in
that they had all undergone a series of structured treat-
ment interruptions, though it is noteworthy that our
ﬁndings were robust across the full period that the
patients were studied. One particular set of individuals
that would be interesting to investigate are patients
enrolled onto post-infection cell-mediated therapeutic
HIV vaccine trials. In our studies, we have used an indir-
ect measure of competition, whereas the gold standard in
studies of competition in whole organism ecology is
experimental manipulations that add or subtract species.
Although, at ﬁrst sight such experiments seem unethical
in humans, post-infection vaccine efﬁcacy studies can be
thought of as experimental manipulations in which
CTLs of certain speciﬁcities are experimentally boosted.
CTL responses pre- and post-vaccination are closely
monitored in HIV vaccine trials and data from vaccinees
would therefore be ideal for testing our prediction that
CTLs speciﬁc for different epitopes do not compete.
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